MBP and Machado-Joseph disease: In agreement with the Luxol Fast Blue staining, Western blot analysis confirmed significantly lower MBP levels in the cerebellum of SCA3 patients compared to controls (Figure 1C), while MBP in the frontal cortex was unchanged (Figure 1D).